Shandong Xinhua Pharmaceutical Company Limited reported that shareholders overwhelmingly backed the appointment of Mr. Liu Weimin as executive director at the 10 November 2026 extraordinary general meeting (EGM), clearing the way for his immediate elevation to Chairman of the 11th Board.

The single ordinary resolution on Mr. Liu’s appointment received 247.56 million votes in favour, equal to 99.81% of votes cast, with only 0.16% against and 0.03% abstaining. Voting participation covered 248.03 million shares—35.60% of the company’s 696.68 million total issued shares—via on-site and online ballots. A-shareholders contributed 209.90 million votes (30.13% of issued shares), while H-shareholders accounted for 38.13 million votes (5.47%).

Mr. Liu’s chairmanship and board tenure begin immediately and will run until the current Board’s term ends on 21 December 2026. Concurrently, outgoing Chairman Mr. He Tongqing resigned from all positions—executive director, chairman, board committee memberships, authorized representative and subsidiary roles—owing to a job change. Mr. He confirmed no disagreements with the Board and no issues requiring shareholder attention.

Governance adjustments include: • Authorized Representative: Mr. Liu replaces Mr. He, joining Mr. Cao Changqiu to meet Hong Kong Listing Rule 3.05 requirements. • Board Committees: Mr. Liu becomes Chairman of the Strategic Development Committee and joins the Nomination Committee following Mr. He’s departure.

All eight directors attended the EGM in person. Grant Thornton Zhitong served as poll scrutineer, and Beijing Jingtian & Gongcheng provided legal verification, both confirming the meeting’s compliance with PRC laws and Hong Kong Listing Rules.